


Application Number 	Application/Control No. 10/667,040	Applicant(s)/Patent under Reexamination MOLLER, CLAUS SCHMIDT	
Document Code - DISQ		Internal Document – DO NOT MAIL	

TERMINAL DISCLAIMER	<input checked="" type="checkbox"/> APPROVED	<input type="checkbox"/> DISAPPROVED
Date Filed : 4/12/07	This patent is subject to a Terminal Disclaimer	

Approved/Disapproved by:
ANDRE ROBINSON

Attorney Docket No.: 6196.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Claus Schmidt Møller

Application No.: 10/667,040

Group Art Unit: 3762

Filed: September 22, 2003

Examiner: Stigell, Theodore J.

For: Injection Device

TERMINAL DISCLAIMER UNDER 37 CFR 1.321

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I am an attorney of record for the instant application.

Novo Nordisk A/S is the assignee of the entire interest in the above-identified application (assignment from the named inventors to Novo Nordisk A/S was recorded in Parent Application 09/882,536 (US Patent No. 6,663,602) on August 27, 2001, Reel 012115, Frame 0942).

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of

U.S. Patent No. 6,663,602, issued December 16, 2003,

is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to

any patent granted on application no. 10/667,040 filed September 23, 2003

this agreement to run with any patent granted on the above-identified application and to be

Patent is
correct

T.S.
4/12/2007

US Application No.: 10/667,040
Filing Date: September 22, 2003

Attorney Docket No.: 6196.210-US
Examiner: Stigell, Theodore J.

binding upon the grantee, its successors and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term of

U.S. Patent No. 6,663, 602, issued December 16, 2003

in the event that the latter later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Please charge the required fee, estimated to be \$110.00, to Novo Nordisk Inc. Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: April 9, 2007



Marc A. Began, Reg. No. 48,829
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE